WallStreetZenWallStreetZen

NASDAQ: SRPT
Sarepta Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SRPT

Based on 6 analysts offering 12 month price targets for Sarepta Therapeutics Inc

Min Forecast
$5.00-70.33%
Avg Forecast
$26.33+56.28%
Max Forecast
$38.00+125.52%

Should I buy or sell SRPT stock?

Based on 6 analysts offering ratings for Sarepta Therapeutics Inc.

Hold
Strong Buy
1 analysts 16.67%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
1 analysts 16.67%
Strong Sell
1 analysts 16.67%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their SRPT stock forecasts and price targets.

SRPT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-16
lockedlocked$00.00+00.00%2026-03-26
lockedlocked$00.00+00.00%2026-03-19
lockedlocked$00.00+00.00%2026-03-13
lockedlocked$00.00+00.00%2026-02-27
Wedbush
Bottom 5%
5
BuyMaintains$34.00+101.78%2026-01-23

1 of 1

Forecast return on equity

Is SRPT forecast to generate an efficient return?

Company
18.77%
Industry
92.18%
Market
176.76%
SRPT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SRPT forecast to generate an efficient return on assets?

Company
8.89%
Industry
27.58%
SRPT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRPT earnings per share forecast

What is SRPT's earnings per share in the next 3 years based on estimates from 27 analysts?

Avg 1 year Forecast
$3.66+510.8%
Avg 2 year Forecast
$0.91+52.37%
Avg 3 year Forecast
$1.36+126.93%
SRPT's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

SRPT revenue forecast

What is SRPT's revenue in the next 3 years based on estimates from 27 analysts?

Avg 1 year Forecast
$1.9B-14.38%
Avg 2 year Forecast
$1.5B-33.06%
Avg 3 year Forecast
$1.5B-32.15%
SRPT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SRPT earnings growth forecast

How is SRPT forecast to perform vs Biotechnology companies and vs the US market?

Company
2.21%
Industry
15.51%
Market
33.86%
SRPT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
SRPT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
SRPT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

SRPT revenue growth forecast

How is SRPT forecast to perform vs Biotechnology companies and vs the US market?

Company
-14.08%
Industry
33.99%
Market
13.34%
SRPT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SRPT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SRPT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SRPT$16.85$26.33+56.28%Hold
BCAX$26.87$31.00+15.37%Strong Buy
ZYME$24.15$46.60+92.96%Strong Buy
GHRS$28.22$41.67+47.65%Strong Buy
NBTX$35.99$37.33+3.73%Buy
View Top Biotech Stocks

Sarepta Therapeutics Stock Forecast FAQ

Is Sarepta Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: SRPT) stock is to Hold SRPT stock.

Out of 6 analysts, 1 (16.67%) are recommending SRPT as a Strong Buy, 3 (50%) are recommending SRPT as a Buy, 0 (0%) are recommending SRPT as a Hold, 1 (16.67%) are recommending SRPT as a Sell, and 1 (16.67%) are recommending SRPT as a Strong Sell.

If you're new to stock investing, here's how to buy Sarepta Therapeutics stock.

What is SRPT's earnings growth forecast for 2026-2028?

(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual earnings growth rate of 2.21% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.86%.

Sarepta Therapeutics's earnings in 2026 is $65,057,000.On average, 27 Wall Street analysts forecast SRPT's earnings for 2026 to be $386,915,738, with the lowest SRPT earnings forecast at $224,518,394, and the highest SRPT earnings forecast at $627,439,487. On average, 26 Wall Street analysts forecast SRPT's earnings for 2027 to be $96,517,782, with the lowest SRPT earnings forecast at -$294,874,388, and the highest SRPT earnings forecast at $336,999,301.

In 2028, SRPT is forecast to generate $143,752,584 in earnings, with the lowest earnings forecast at $69,321,347 and the highest earnings forecast at $257,183,677.

What is SRPT's revenue growth forecast for 2026-2028?

(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -14.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.

Sarepta Therapeutics's revenue in 2026 is $2,184,184,000.On average, 27 Wall Street analysts forecast SRPT's revenue for 2026 to be $197,427,535,140, with the lowest SRPT revenue forecast at $175,678,833,408, and the highest SRPT revenue forecast at $227,833,487,076. On average, 26 Wall Street analysts forecast SRPT's revenue for 2027 to be $154,352,436,564, with the lowest SRPT revenue forecast at $91,113,335,348, and the highest SRPT revenue forecast at $207,457,276,230.

In 2028, SRPT is forecast to generate $156,463,961,004 in revenue, with the lowest revenue forecast at $124,052,060,850 and the highest revenue forecast at $188,664,708,714.

What is SRPT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SRPT) forecast ROA is 8.89%, which is lower than the forecast US Biotechnology industry average of 27.58%.

What is SRPT's Price Target?

According to 6 Wall Street analysts that have issued a 1 year SRPT price target, the average SRPT price target is $26.33, with the highest SRPT stock price forecast at $38.00 and the lowest SRPT stock price forecast at $5.00.

On average, Wall Street analysts predict that Sarepta Therapeutics's share price could reach $26.33 by Apr 16, 2027. The average Sarepta Therapeutics stock price prediction forecasts a potential upside of 56.28% from the current SRPT share price of $16.85.

What is SRPT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SRPT) Sarepta Therapeutics's current Earnings Per Share (EPS) is $0.60. On average, analysts forecast that SRPT's EPS will be $3.66 for 2026, with the lowest EPS forecast at $2.13, and the highest EPS forecast at $5.94. On average, analysts forecast that SRPT's EPS will be $0.91 for 2027, with the lowest EPS forecast at -$2.79, and the highest EPS forecast at $3.19. In 2028, SRPT's EPS is forecast to hit $1.36 (min: $0.66, max: $2.44).

What is SRPT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SRPT) forecast ROE is 18.77%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.